Specific adverse events: serioushypertension · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serioushypertension compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Cediranib plus chemotherapy showed no clear difference in serious adverse events compared with placebo plus chemotherapy (low certainty).
1 finding from 1 review
Economic evaluation ‐ not measured · women with persistent, recurrent, or metastatic cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · women with persistent, recurrent, or metastatic cervical cancer
Cediranib plus chemotherapy showed no clear difference in overall survival compared with placebo plus chemotherapy (low certainty).
1 finding from 1 review
Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: gastrointestinal perforations or fistulae compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Pelvic pain · women having endometriosis surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pelvic pain · women having endometriosis surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain recurrence (dichotomous) Pain recurrence ≤ 12 months · women having endometriosis surgery
Presurgical medical therapy showed no clear difference in pain recurrence (dichotomous) Pain recurrence ≤ 12 months compared with postsurgical medical therapy (low certainty).
1 finding from 1 review
Disease recurrence at 12 months – total (AFS score) · women having endometriosis surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence · women having endometriosis surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease recurrence ≤ 12 months (EEC stage) · women having endometriosis surgery
It is very uncertain whether presurgical medical therapy changes disease recurrence ≤ 12 months (EEC stage) compared with postsurgical medical therapy (very low certainty).
1 finding from 1 review
Pregnancy rate · women having endometriosis surgery
It is very uncertain whether presurgical medical therapy changes pregnancy rate (dichotomous) compared with postsurgical medical therapy (very low certainty).
1 finding from 1 review
Pain recurrence (dichotomous) Pain recurrence ≤ 12 months · women having endometriosis surgery
It is very uncertain whether presurgical medical therapy changes pain recurrence (dichotomous) Pain recurrence ≤ 12 months compared with placebo or no medical therapy (very low certainty).
1 finding from 1 review
Disease recurrence at 3 months – total (AFS score) · women having endometriosis surgery
1 finding from 1 review
Recurrence · women having endometriosis surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease recurrence ≤ 12 months (EEC stage) · women having endometriosis surgery
It is very uncertain whether presurgical medical therapy changes disease recurrence ≤ 12 months (EEC stage) compared with placebo or no medical therapy (very low certainty).
1 finding from 1 review
Pregnancy rate · women having endometriosis surgery
It is very uncertain whether presurgical medical therapy changes pregnancy rate (dichotomous) compared with placebo or no medical therapy (very low certainty).
1 finding from 1 review
Maximal treadmill walking distance after 3 months · intermittent claudication
1 finding from 1 review
Pain‐free walking distance · intermittent claudication
1 finding from 1 review
Quality of Life: SF‐36 (physical component) · intermittent claudication
1 finding from 1 review